Roles for ghrelin in the regulation of appetite and body weight

Current Opinion in Endocrinology and Diabetes

Volumn 12, Issue 1, 2005, Pages 72-79

  Cummings, David E ^a,b   Overduin, Joost ^a   Foster Schubert, Karen E ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Body weight regulation; Energy homeostasis; Ghrelin; Meals; Obesity; Weight loss

Indexed keywords

APPETITE STIMULANT; GHRELIN;

BODY WEIGHT; ENERGY EXPENDITURE; FOOD INTAKE; HORMONE ACTION; OBESITY; PRADER WILLI SYNDROME; REVIEW; STOMACH BYPASS; WASTING SYNDROME; WEIGHT GAIN;

EID: 14944366824     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000152035.62993.5a     Document Type: Review

References (93)

1. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
2. Tschop M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature 2000; 407:908-913.
3. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141:4325-4328.
4. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409:194-198.
5. van der Lely AJ, Tschop M, Heiman ML, et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25:426-457. This is the most encyclopedic published review on ghrelin, written by some of the most prolific authors in the field. It covers the full breadth of known and hypothesized biologic roles for ghrelin. Beyond describing well-documented aspects of ghrelin's regulation and actions, the authors also tackle controversial issues, such as the possibilities of alternate receptors for ghrelin, alternate ligands for the ghrelin receptor, physiologic roles for des-acyl ghrelin, and the biologic importance of centrally produced ghrelin.
6. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141:4255-4261.
7. Korbonits M, Bustin SA, Kojima M, et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86:881-887.
8. Thompson NM, Gill DA, Davies R, et al. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 2004; 145:234-242.
9. Muccioli G, Pons N, Ghe C, et al. Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol 2004; 498:27-35.
10. Gauna C, Meyler FM, Janssen JA, et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 2004; 89:5035-5042. Among the handful of studies that claim biologic roles for des-acyl ghrelin, this is one of the few performed in humans. The authors report that administration of acylated ghrelin increased blood glucose and insulin levels - effects that were prevented by concomitant injection of des-acyl ghrelin.
11. Cassoni P, Ghe C, Marrocco T, et al. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol 2004; 150:173-184.
12. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159:1029-1037.
13. Bedendi I, Alloatti G, Marcantoni A, et al. Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol 2003; 476:87-95.
14. Halem HA, Taylor JE, Dong JZ, et al. Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol 2004; 151(suppl 1):S71-S75.
15. Ariyasu H, Takaya K, Iwakura H, et al. Transgenic mice overexpressing desacyl ghrelin show small phenotype. Endocrinology 2004 [Epub ahead of print]. Transgenic mice overexpressing des-acyl ghrelin ubiquitously, with circulating levels increased 10- to 44-fold, showed reductions in body weight, axial length, insulin-like growth factor-1 levels, and the GH response to ghrelin, suggesting that very high levels of des-acyl ghrelin may block some of the actions of acylated ghrelin.
16. Broglio F, Gottero C, Prodam F, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004; 89:3062-3065. In humans, coinjection of des-acyl ghrelin blocked the effect of exogenous acylated ghrelin to increase glucose and decrease insulin levels, but had no effect on acylated ghrelin's stimulation of GH, ACTH, cortisol, or prolactin.
17. Sun Y, Wang P, Zheng H, et al. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A 2004; 101:4679-4684. Using GHS-R knockout mice, the authors prove that this receptor mediates the effects of ghrelin on food intake and GH. The mice display modest decreases in insulin-like growth factor-1 levels and body weight.
18. Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004; 145:2607-2612. This paper proves that NPY and Agrp mediate the orexigenic effects of ghrelin and GH secretagogues, demonstrating that these effects are absent in mice lacking both genes. The paper does not settle the question of whether hypothalamic NPY/Agrp neurons are primarily first-order targets of circulating ghrelin (acting as a hormone), targets of hypothalamic ghrelin (acting as a neuropeptide), or required components of an indirect pathway relaying ghrelin signaling from the vagus and/or hindbrain.
19. Holst B, Cygankiewicz A, Jensen TH, et al. High constitutive signaling of the ghrelin receptor: identification of a potent inverse agonist. Mol Endocrinol 2003; 17:2201-2210. This paper shows that ghrelin can signal not only through the canonical Gq/phospholipase C pathway, but also via Gs/protein kinase A, and that the ghrelin receptor exhibits substantial ligand-independent constitutive activity.
20. Holst B, Holliday ND, Bach A, et al. Common structural basis for constitutive activity of the ghrelin receptor family. J Biol Chem 2004 [Epub ahead of print]. The high constitutive activity of the ghrelin receptor is shown to exist in other members of this receptor family and to be determined by an aromatic cluster on the inner face of the extracellular ends of transmembrane segments VI and VII.
21. Bednarek MA, Feighner SD, Pong SS, et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 2000; 43:4370-4376,
22. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86:4753-4758.
23. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87:2988-2991.
24. Sakata I, Nakamura K, Yamazaki M, et al. Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 2002; 23:531-536.
25. Krsek M, Rosicka M, Haluzik M, et al. Plasma ghrelin levels in patients with short bowel syndrome. Endocr Res 2002; 28:27-33.
26. Prado CL, Pugh-Bernard AE, Elghazi L, et al. Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc Natl Acad Sci U S A 2004; 101:2924-2929. A novel, ghrelin-producing ε-cell type is identified in pancreatic islets and is shown to replace β cells when development of the latter is ablated by deleting key transcription factor genes.
27. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37:649-661. The authors provide a detailed description of immunoreactive ghrelin neurons, with cell bodies positioned between traditional hypothalamic nuclei, projecting to NPY/Agrp neurons as well as other cells involved in energy homeostasis. They also report that ghrelin mRNA can be detected in the brain using RT-PCR.
28. Wortley KE, Anderson KD, Garcia K, et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A 2004; 101:8227-8232. Ghrelin knockout mice show a very subtle phenotype, with no detectable GH abnormalities, but increased fat catabolism and a modest lean phenotype revealed on a high-fat diet.
29. Sun Y, Ahmed S, Smith RG: Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003; 23:7973-7981. These authors detect no apparent defects in energy homeostasis among ghrelin-deficient mice.
30. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001; 120:337-345.
31. Faulconbridge LF, Cummings DE, Kaplan JM, et al. Hyperphagic effects of brainstem ghrelin administration. Diabetes 2003; 52:2260-2265. This paper shows that the primary effect of ICV-administered ghrelin on meal patterns is to increase meat initiation, and that ghrelin injections in the hindbrain potently stimulate food intake.
32. Masuda Y, Tanaka T, Inomata N, et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000; 276:905-908.
33. Cummings DE, Shannon MH: Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003; 138:389-396. This review of ghrelin's anabolic actions places special focus on the effects of bariatric surgery on ghrelin levels.
34. Lu XY, Shieh KR, Kabbaj M, et al. Diurnal rhythm of agouti-related protein and its relation to corticosterone and food intake. Endocrinology 2002; 143:3905-3915.
35. ShiiyaT, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion, J Clin Endocrinol Metab 2002; 87:240-244.
36. Williams DL, Cummings DE, Grill HJ, Kaplan JM: Meal-related ghrelin suppression requires postgastric feedback. Endocrinology 2003; 144:2765-2767. Using rats fitted with pyloric cuffs, the authors show that nutrients constrained within the stomach do not affect ghrelin levels.
37. Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24:RC19-RC21.
38. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50:1714-1719.
39. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346:1623-1630.
40. Weigle DS, Cummings DE, Newby PD, et al. Roles of leptin and ghrelin in the loss of body weight caused by a low fat, high carbohydrate diet. J Clin Endocrinol Metab 2003; 88:1577-1586. This paper shows that, unlike most modes of weight loss, that achieved with a low-fat diet does not elicit a compensatory increase in plasma ghrelin levels at any time throughout 24-hour profiles.
41. Wren AM, Seal U, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86:5992-5995.
42. Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001; 50:2540-2547.
43. Sugino T, Yamaura J, Yamagishi M, et al. A transient surge of ghrelin secretion before feeding is modified by different feeding regimens in sheep. Biochem Biophys Res Commun 2002; 298:785-788.
44. Cummings DE, Frayo RS, Marmonier C, et al. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 2004; 287:E297-E304. This work shows that preprandial surges of plasma ghrelin levels occur in people initiating meals spontaneously, in the absence of time- and food-related cues. Moreover, the temporal profile of ghrelin levels overlaps tightly with that of subjective hunger scores in this setting.
45. Tolle V, Bassant MH, Zirzari P, et al. Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behavior, and sleep-wake patterns in rats. Endocrinology 2002; 143:1353-1361.
46. Callahan HS, Cummings DE, Pepe MS, et al. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab 2004; 89:1319-1324. This paper shows that the depth and duration of postprandial ghrelin suppression are proportional to the number of calories ingested, when all features of the meal other than caloric content are held constant.
47. Overduin J, Frayo RS, Grill HJ, et al. Role of the duodenum and macronutrient type in ghrelin regulation. Endocrinology 2004 [Epub ahead of print]. This work demonstrates that the stomach and duodenum - the principal sites of ghrelin synthesis - are not required for enteral nutrient-related ghrelin suppression. It also shows that lipids suppress ghrelin levels relatively poorly, compared with glucose or amino acids.
48. Gelling RW, Overduin J, Morrison CD, et al. Effect of uncontrolled diabetes on plasma ghrelin concentrations and ghrelin-induced feeding. Endocrinology 2004; 145:4575-4582. Using the β-cell toxin streptozotocin, the authors show that insulin contributes to, but is not entirely required for, enteral nutrient-related ghrelin suppression in rats.
49. Williams DL, Grill HJ, Cummings DE, et al. Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 2003; 144:5184-5187. This work demonstrates that the vagus nerve is not required for short-term, prandial ghrelin regulation, but it is required for the increase of ghrelin levels that accompanies longer term weight loss.
50. Cummings DE, Schwarte MW: Genetics and pathophysiology of human obosity. Annu Rev Med 2003; 54:453-471. This is a broad review of energy homeostasis, emphasizing neuroendocrine control and genetic influences on body weight.
51. Schwartz MW, Woods SC, Porte D, et al. Central nervous system control of food intake. Nature 2000; 404:661-671.
52. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50:707-709.
53. Cummings DE, Clement K, Purnell JQ, et al. Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat Med 2002; 8:643-644.
54. Tolle V, Kadem M, Bluet-Pajot MT, et al. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab 2003; 88:109-116.
55. Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145:669-673.
56. Haqq AM, Farooqi IS, O'Rahilly S, et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 2003; 88:174-178.
57. Wisse BE, Frayo RS, Schwartz MW, et al. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001; 142:3292-3301.
58. Hansen TK, Dall R, Hosoda H, et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 2002; 56:203-206.
59. Shimizu Y, Noritoshi N, Isobe T, et al. Increased plasma ghrelin levels in lung cancer cachexia. Clin Cancer Res 2003; 9:774-778.
60. Popovic V, Svetel M, Djurovic M, et al. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. Eur J Endocrinol 2004; 151:451-455.
61. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001; 104:2034-2038.
62. Itoh T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin level in under-weight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:879-882.
63. Tacke F, Brabant G, Kruck E, et al. Ghrelin in chronic liver disease. J Hepatol 2003; 38:447-454.
64. Yoshimoto A, Mori K, Sugawara A, et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 2002; 13:2748-2752.
65. Otto B, Tschop M, Heldwein W, et al. Endogenous and exogenous glucocorticoids decrease plasma ghrelin in humans. Eur J Endocrinol 2004; 151:113-117.
66. 65a Foster-Schubert KE, McTiernan A, Frayo RS, et al. Human plasma ghrelin levels increase during a one-year exercise program. J Clin Endocrinol Metab 2004; [Epub ahead of print].
67. McLaughlin T, Abbasi F, Lamendola C, et al. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab 2004; 89:1630-1635.
68. Purnell JQ, Weigle DS, Breen P, et al. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab 2003; 88:5747-5752.
69. Cummings DE, Foster KE: Ghrelin-leptin tango in body-weight regulation. Gastroenterology 2003; 124:1532-1535. This paper presents evidence indicating that leptin does not physiologically regulate ghrelin levels, and that it is more likely that ghrelin-producing cells sense changes in body weight via alterations in insulin levels.
70. Astrup A, Astrup A, Buemann B, et al. Low-fat diets and energy balance: how does the evidence stand in 2002. Proc Nutr Soc 2002; 61:299-309.
71. Cummings DE, Shannon MH: Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 2003; 88: 2999-3002.
72. Cummings DE, Overduin J, Foster-Schubert KE: Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004; 89:2608-2615. This paper discusses hormonal mechanisms that may contribute to weight loss and resolution of diabetes following bariatric surgery.
73. Banks WA, Tschop M, Robinson SM, et al. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002; 302:822-827.
74. Willesen MG, Kristensen P, Romer J: Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 1999; 70:306-316.
75. Dickson SL, Luckman SM: Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology 1997; 138:771-777.
76. Kamegai J, Tamura H, Shimizu T, et al. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 2000; 141:4797-4800.
77. Kamegai J, Tamura H, Shimizu T, et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes 2001; 50:2438-2443.
78. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50:227-232.
79. Date Y, Murakami N, Toshinai K, et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002; 123:1120-1128.
80. Xie QF, Wu CX, Meng QY, et al. Ghrelin and truncated ghrelin variant plasmid vectors administration into skeletal muscle augments long-term growth in rats. Dornest Anim Endocrinol 2004; 27:155-164. Plasmid vector overexpression of either ghrelin or a 7-amino-acid N-terminal fragment increases body weight and GH levels for at least a month in rats.
81. Shimbara T, Mondai MS, Kawagoe T, et al. Central administration of ghrelin preferentially enhances fat ingestion. Neurosci Lett 2004; 369:75-79. Central ghrelin injections selectively increase fat ingestion, both in fat-preferring and carbohydrate-preferring rats.
82. Kim MS, Yoon CY, Jang PG, et al. The mitogenic and antiapoptotic actions of ghrelin in 3T3-L1 adipocytes. Mol Endocrinol 2004; 18:2291-2301.
83. Matsumura K, Tsuchihashi T, Fujii K, et al. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002; 40:694-699.
84. Lawrence CB, Snape AC, Baudoin FM, et al. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 2002; 143:155-162.
85. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114:57-66. Ghrelin suppressed baseline and leptin-induced expression of anorexic, proinflammatory cytokines (interleukin-1β, interleukin-6, and tumor necrosis factor-α) by monocytes and T cells, in addition to decreasing inflammation and endotoxin-induced anorexia in mice.
86. Tang-Christensen M, Vrang N, Ortmann S, et al. Central administration of ghrelin and agouti-related protein (83-132) increases food intake and decreases spontaneous locomotor activity in rats. Endocrinology 2004; 145: 4645-4652. Adding to the list of mechanisms by which ghrelin can promote weight gain, the authors show that ghrelin (and Agrp, but not NPY) decrease spontaneous locomotor activity in rats.
87. Tsolakis AV, Portela-Gomes GM, Stridsberg M, et al. Malignant gastric ghrelinoma with hyperghrelinemia. J Clin Endocrinol Metab 2004; 89:3739-3744. In the first human case of ghrelin gain-of-function, the authors describe a man who died of a malignant ghrelinoma that overproduced acylated ghrelin. He maintained his appetite and remained obese throughout a 15-month course of several chemotherapy regimens, culminating in death from metastatic cancer.
88. Murakami N, Hayashida T, Kuroiwa T, et al. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J Endocrinol 2002; 174:283-288.
89. Bagnasco M, Tulipano G, Melis MR, et al. Endogenous ghrelin is an orexigenic peptide acting in the arcuate nucleus in response to fasting. Regul Pept 2003; 111:161-167.
90. Asakawa A, Inui A, Kaga T, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003; 52:947-952. This works describes two relatively low-potency, high-dose ghrelin receptor antagonists, which decrease food intake, body weight, and fat mass in lean, diet-induced obese, and leptin-deficient mice. The authors do not prove that these effects are specifically mediated via the ghrelin receptor.
91. Shuto Y, Shibasaki T, Otagiri A, et al. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 2002; 109:1429-1436.
92. Helmling S, Maasch C, Eulberg D, et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad Sci U S A 2004; 101:13174-13179. Biostable L-enantiomer RNA-based compounds that specifically and avidly bind to the N-terminus of acylated ghrelin block ghrelin's ability to activate its receptor in vitro and to stimulate GH in vivo.
93. Ukkola O, Ravussin E, Jacobson P, et al. Role of ghrelin polymorphisms in obesity based on three different studies. Obes Res 2002; 10:782-791.